PMID- 16251077
OWN - NLM
STAT- MEDLINE
DCOM- 20070529
LR  - 20181201
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 85
IP  - 24
DP  - 2005 Jun 29
TI  - [Effect of human placenta derived mesenchymal stem cells on cord blood lymphocyte 
      transformation].
PG  - 1704-7
AB  - OBJECTIVE: To study the effect of human placenta derived mesenchymal stem cells 
      (MSCs) on the immune function of lymphocytes derived from human umbilical cord 
      blood. METHODS: Mononucleated cells (MNC) were isolated from human placenta 
      tissue perfusate by density gradient fractionation. Individual colonies were 
      selected and cultured. The culture-expanded cells were characterized by immune 
      phenotyping so as to identify the MSCs. The MSCs were cultured under conditions 
      promoting differentiation to osteoblasts or adipocytes. MNCs were isolated from 
      adult peripheral blood and human umbilical cord blood and cultured, then the 
      adherent cells were excluded and the suspended cells, lymphocytes, were 
      inoculated in the culture fluids of MSCs of different concentrations and 
      phytohemagglutinin (PHA), a nonspecific mitogenic stimulant, was added for 84 
      hours (MSC + PHA groups), then (3)H-thymidine deoxyribose ((3)H-TdR) was added 
      for 12 hours. The cells were collected and scintillation counter was used to 
      calculate the counts per minute (cpm). Pure lymphocytes without MSC and 
      stimulated by PHA were used as control group (non-MSC Group) and pure lymphocytes 
      and pure MSCs without PHA were used as blank control groups (non-PHA Group). 
      RESULTS: From human placenta MSCs were successfully isolated and exhibited 
      fibroblast-like morphology. Flow cytometric analysis showed that the placental 
      MSCs were a homogeneous cell population devoid of hematopoietic cells positive 
      for CD29, CD44, CD73, CD105, CD166, and HLA-ABC positive and negative for CD34, 
      CD45, and HLA-DR. They could be induced into adipocytes or osteocytes. The cpm 
      value of the non-MSC Group was 171 855 +/- 31 454, significantly higher than that 
      of non-PHA Group (26 453 +/- 5268). The cpm values of the different 
      concentrations MSC + PHA groups were all significantly lower than that of non-MSC 
      Group in a dose-dependent manner; when the dose of MSCs was 2 x 10(5) the 
      suppression rate was 79.97% in PB and 64.06% in UCB. CONCLUSION: MSCs derived 
      from postpartum human placenta, an important and novel source of multipotent stem 
      cells, suppress blood lymphocyte proliferation, thus may be used to reduce graft 
      -versus-host disease (GVHD) in recipients.
FAU - Li, Chang-dong
AU  - Li CD
AD  - Department of Gynecology, Beijing Gynecology and Obstetrics Hospital, Capital 
      University of Medical Sciences, Beijing 100026, China.
FAU - Zhang, Wei-yuan
AU  - Zhang WY
FAU - Li, He-lian
AU  - Li HL
FAU - Jiang, Xiao-xia
AU  - Jiang XX
FAU - Zhang, Yi
AU  - Zhang Y
FAU - Mao, Ning
AU  - Mao N
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
SB  - IM
MH  - Cells, Cultured
MH  - Female
MH  - Fetal Blood/cytology
MH  - Humans
MH  - *Lymphocyte Activation
MH  - Lymphocytes/*immunology
MH  - Mesenchymal Stem Cells/*cytology
MH  - Placenta/*cytology
EDAT- 2005/10/28 09:00
MHDA- 2007/05/30 09:00
CRDT- 2005/10/28 09:00
PHST- 2005/10/28 09:00 [pubmed]
PHST- 2007/05/30 09:00 [medline]
PHST- 2005/10/28 09:00 [entrez]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2005 Jun 29;85(24):1704-7.